Our lead programs are focused in the areas of cancer, inflammation, fibrosis with other indications to come as the platform continues to mature. f5 Therapeutics places a premium on tackling highly prevalent diseases with no treatment options, such as NASH.  Our goal is to develop our extensive pipeline through early-stage Phase 1 proof of concept via partnerships with global leaders in each therapeutic category.

f5 Pipeline_9-19.jpg

NK Activation Program: The presence of Natural Killer cells within a tumor has been associated with a favorable prognosis in cancer and but show decreased activity in the immune suppressive tumor microenvironment (TME).  A potential mechanism to restore NK cell activity is degradation of known, transcriptional repressor neosubstrates. 

Wnt-Dependent Disease:  β-catenin -driven liver cancer represents 30% of all hepatocellular carcinoma (HCC) and are characterized by a suppressive or “cold” immune cell microenvironment limiting checkpoint therapy effectiveness.  

NF-KB Modulation: Activated hepatic stellate cells (HSC) are the central driver of liver fibrosis.  Antagonizing altered β-catenin signaling or modulation of NF-KB signaling in activated HSCs represent a therapeutically valuable approach for liver fibrosis.